Skip to main content
Top
Published in: Clinical Rheumatology 7/2008

01-07-2008 | Original Article

TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis

Authors: Silvia Bosello, Angelo Santoliquido, Angelo Zoli, Cristiana Di Campli, Roberto Flore, Paolo Tondi, GianFranco Ferraccioli

Published in: Clinical Rheumatology | Issue 7/2008

Login to get access

Abstract

Considerable evidence indicates that patients with rheumatoid arthritis (RA) are at greater risk of developing atherosclerosis and cardiovascular disease. Recent studies support the predictive ability of endothelial function measures for subsequent atherosclerotic events. We have investigated the effects of infliximab, a chimeric monoclonal anti-tumor necrosis factor (TNF) antibody, on endothelial vasodilation, measured by brachial ultrasonography and on the levels of inflammatory biomarkers and adhesion molecules in ten consecutive patients with severe long-standing RA, despite methotrexate therapy, during the loading phase of infliximab therapy. Flow-mediated dilation (FMD) in RA patients at baseline was significantly impaired compared with healthy controls (7.71 ± 2.78% vs 14.91 ± 6.41%; p = 0.008) and improved significantly after infliximab infusion (12.63 ± 1.63% vs 7.71 ± 2.78%; p = 0.005). At baseline, a statistically significant correlation between C-reactive protein levels and FMD was found (r = −0.69, p = 0.026). However, this improvement was transitory, as FMD values returned to baseline values before each infliximab infusion at weeks 2, 6 and 14. There were no significant differences in baseline brachial artery diameter between visits, although at each time, the diameter was increased. According to European League Against Rheumatism response criteria, all ten patients were good responders. No significant differences were observed in intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, vascular endothelial growth factor and E-selectin plasma levels before and after each infusions. This study demonstrates that endothelial dysfunction is a reversible phenomenon in RA. The addition of anti-TNFα treatment reduces inflammatory symptoms in patients with severe RA. The improvement of endothelial function during the loading phase of therapy is transitory, suggesting an enhanced and persistent TNF-α generation within the arterial wall.
Literature
1.
go back to reference Van Doornum S, McColl G, Wicks IP et al (2002) Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRef Van Doornum S, McColl G, Wicks IP et al (2002) Accelerated atherosclerosis. An extraarticular feature of rheumatoid arthritis. Arthritis Rheum 46:862–873PubMedCrossRef
2.
go back to reference Ferraccioli GF, Gremese E (2004) Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis 63:613–615PubMedCrossRef Ferraccioli GF, Gremese E (2004) Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers. Ann Rheum Dis 63:613–615PubMedCrossRef
3.
go back to reference Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(S2):1–12PubMed Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(S2):1–12PubMed
4.
go back to reference Symmons DP, Jones MA, Scott DL et al (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed Symmons DP, Jones MA, Scott DL et al (1998) Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well. J Rheumatol 25:1072–1077PubMed
5.
go back to reference Pasceri V, Yeh ET (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100:2124–2126PubMed Pasceri V, Yeh ET (1999) A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 100:2124–2126PubMed
6.
go back to reference Bacon PA, Stevens RJ, Carruthers DM et al (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1:338–347PubMedCrossRef Bacon PA, Stevens RJ, Carruthers DM et al (2002) Accelerated atherogenesis in autoimmune rheumatic diseases. Autoimmun Rev 1:338–347PubMedCrossRef
7.
go back to reference Pradhan AD, Rifai N, Ridker PM (2002) Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 106:820–825PubMedCrossRef Pradhan AD, Rifai N, Ridker PM (2002) Soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, and the development of symptomatic peripheral arterial disease in men. Circulation 106:820–825PubMedCrossRef
8.
go back to reference Hurlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187PubMedCrossRef Hurlimann D, Forster A, Noll G et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106:2184–2187PubMedCrossRef
9.
go back to reference Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2004) Transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 51:447–450PubMedCrossRef Gonzalez-Juanatey C, Testa A, Garcia-Castelo A et al (2004) Transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor α antibody. Arthritis Rheum 51:447–450PubMedCrossRef
10.
go back to reference Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
11.
go back to reference Van Gestel AM, Prevoo ML, Van’t Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum 39:34–40PubMedCrossRef Van Gestel AM, Prevoo ML, Van’t Hof MA et al (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League against Rheumatism Criteria. Arthritis Rheum 39:34–40PubMedCrossRef
12.
go back to reference Coretti MC, Anderson TJ, Benjamin EJ, International Brachial Artery Reactivity Task Force et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 16:257–265CrossRef Coretti MC, Anderson TJ, Benjamin EJ, International Brachial Artery Reactivity Task Force et al (2002) Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 16:257–265CrossRef
13.
go back to reference Del Rincon I, Freeman GL, Haas RW et al (2005) A Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 52:3413–3423PubMedCrossRef Del Rincon I, Freeman GL, Haas RW et al (2005) A Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 52:3413–3423PubMedCrossRef
14.
go back to reference Wang P, Ba ZF, Chaudry IH (1994) Administration of tumor necrosis factorα in vivo depresses endothelium dependent relaxation. Am J Physiol 266:2535–2541 Wang P, Ba ZF, Chaudry IH (1994) Administration of tumor necrosis factorα in vivo depresses endothelium dependent relaxation. Am J Physiol 266:2535–2541
15.
go back to reference Young JL, Libby P, Schonbeck U (2002) Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88:554–567PubMed Young JL, Libby P, Schonbeck U (2002) Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 88:554–567PubMed
18.
go back to reference Lundman P, Eriksson MJ, Stuhlinger M et al (2001) Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38:111–116PubMedCrossRef Lundman P, Eriksson MJ, Stuhlinger M et al (2001) Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38:111–116PubMedCrossRef
19.
go back to reference Al Suwaidi J, Higano ST, Holmes DR et al (2001) Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37:1523–1528PubMedCrossRef Al Suwaidi J, Higano ST, Holmes DR et al (2001) Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 37:1523–1528PubMedCrossRef
20.
go back to reference Arcaro G, Cretti A Balzano S et al (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576–582PubMedCrossRef Arcaro G, Cretti A Balzano S et al (2002) Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105:576–582PubMedCrossRef
21.
go back to reference Clarkson P, Celermajer DS, Donald AE et al (1996) Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 28:573–579PubMedCrossRef Clarkson P, Celermajer DS, Donald AE et al (1996) Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 28:573–579PubMedCrossRef
22.
go back to reference Kuvin JT, Patel AR, Sliney KA et al (2001) Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 38:1843–1849PubMedCrossRef Kuvin JT, Patel AR, Sliney KA et al (2001) Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 38:1843–1849PubMedCrossRef
23.
go back to reference Anderson TJ, Uehata A, Gerhard MD et al (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235PubMedCrossRef Anderson TJ, Uehata A, Gerhard MD et al (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235PubMedCrossRef
24.
go back to reference Irace C, Mancuso G, Fiaschi E et al (2004) Effect of anti TNFα therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177:113–118PubMedCrossRef Irace C, Mancuso G, Fiaschi E et al (2004) Effect of anti TNFα therapy on arterial diameter and wall shear stress and HDL cholesterol. Atherosclerosis 177:113–118PubMedCrossRef
25.
go back to reference Vaudo G, Marchesi S, Gerli R et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35PubMedCrossRef Vaudo G, Marchesi S, Gerli R et al (2004) Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 63:31–35PubMedCrossRef
26.
go back to reference Gonzalez-Juanatey C, Llorca J, Sanchez Andrade A et al (2006) Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24:309–312PubMed Gonzalez-Juanatey C, Llorca J, Sanchez Andrade A et al (2006) Short-term adalimumab therapy improves endothelial function in patients with rheumatoid arthritis refractory to infliximab. Clin Exp Rheumatol 24:309–312PubMed
27.
go back to reference Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM et al (2006) Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients withrheumatoid arthritis. Clin Exp Rheumatol 24:373–379PubMed Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM et al (2006) Influence of anti-TNF-α infliximab therapy on adhesion molecules associated with atherogenesis in patients withrheumatoid arthritis. Clin Exp Rheumatol 24:373–379PubMed
28.
go back to reference Mäki-Petäjä K, Hall FC, Booth AD et al (2006) Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114:1185–1192PubMedCrossRef Mäki-Petäjä K, Hall FC, Booth AD et al (2006) Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-α therapy. Circulation 114:1185–1192PubMedCrossRef
29.
go back to reference Van Doornum S, Mc Coll G, Wicks IP (2005) Tumor necrosis factor antagonists improve disease activity but not arterial stiffness in RA. Rheumatology 44:1428–1432PubMedCrossRef Van Doornum S, Mc Coll G, Wicks IP (2005) Tumor necrosis factor antagonists improve disease activity but not arterial stiffness in RA. Rheumatology 44:1428–1432PubMedCrossRef
30.
go back to reference Bilsborough W, Keen H, Taylor A et al (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125–1131PubMedCrossRef Bilsborough W, Keen H, Taylor A et al (2006) Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 26:1125–1131PubMedCrossRef
31.
go back to reference Cardillo C, Schinzari F, Mores N et al (2006) Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 80:275–281PubMedCrossRef Cardillo C, Schinzari F, Mores N et al (2006) Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. Clin Pharmacol Ther 80:275–281PubMedCrossRef
Metadata
Title
TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis
Authors
Silvia Bosello
Angelo Santoliquido
Angelo Zoli
Cristiana Di Campli
Roberto Flore
Paolo Tondi
GianFranco Ferraccioli
Publication date
01-07-2008
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 7/2008
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0803-y

Other articles of this Issue 7/2008

Clinical Rheumatology 7/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.